“…it’s no wonder that every big drug company wants to be “Partner of Choice” with smaller innovators. Nearly every pharma has hired consultants at some point to help it position its BD strategy more effectively.” – Bruce Booth, “Transformational Late Stage Drugs Delivered Through Deal Making,” Forbes, 3/21/14

“ …it’s a widely-held belief that a critical element of exceptional R&D organizations in the future will be creative BD engagement. In short, great BD and R&D are becoming synonymous with each other.” – Bruce Booth, “External Innovation: Force Multiplier For R&D,” Forbes, 6/26/2015

“The past two years (2013-2014) have seen more IPOs (173) than the cumulative total of the prior decade…M&A has also been strong…biotech has seen 85 “big exits” over the past six years reaching an average upfront and total deal value of $366M and $507M in 2014 (30-50% higher than just five years ago).” – Bruce Booth, “Startups, Exits, and Ecosystem Flux: Bullish for Biotech” Forbes, 9/8/2014

“Nearly $26B in real or potentially liquid distributions have been generated over the past two years alone. This is 3-4x more than has been invested over that period of time by VCs into biotech; distributions vastly outstripping investments is certainly positive biomarker for the venture sector.” – Bruce Booth, “Venture Backed Biotech Today, Bruce Booth, Forbes 1/22/15